SCHEMBL490703

SCHEMBL490703

CCOC(=O)C(C)c1cc(O)cc(O)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 6/20 0.53
CA1 P00915 6/20 0.53
CA2 P00918 6/20 0.53
CA7 P43166 6/20 0.53
CA9 Q16790 6/20 0.53
CA14 Q9ULX7 6/20 0.53
NR1H2 P55055 1/20 0.47
NR1H3 Q13133 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.43
CYP3A4 P08684 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
ESR1 P03372 1/20 0.40
ESR2 Q92731 1/20 0.40
TSHR P16473 2/20 0.38
HIF1A Q16665 1/20 0.38
ADRB2 P07550 1/20 0.38
ADRA1A P35348 1/20 0.38
TYR P14679 1/20 0.38
LMNA P02545 2/20 0.37
PSEN1 P49768 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL491002 0.83 CYP3A4 (0.43) CA12CA1CA2CA7CA9
SCHEMBL27909593 0.82 TSHR (0.39) CA12CA1CA2CA7CA9
SCHEMBL31074078 0.82 ADRB1 (0.45) CA12CA1CA2CA7CA9
SCHEMBL3905021 0.82 ADRB1 (0.45) CA12CA1CA2CA7CA9
SCHEMBL1792502 0.81 ESR1 (0.53) CA12CA1CA2CA7CA9
SCHEMBL9235662 0.81 ESR1 (0.53) CA12CA1CA2CA7CA9
SCHEMBL9232941 0.81 ESR1 (0.53) CA12CA1CA2CA7CA9
SCHEMBL5050127 0.80 MT-CO2 (0.47) CA12CA1CA2CA7CA9
SCHEMBL7219204 0.79 TSHR (0.37) CA12CA1CA2CA7CA9
SCHEMBL2131626 0.79 LMNA (0.42) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8268293-B2 Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives MERCK PATENT GMBH (DE) 2012-09-18 US disclosed
CN-101163659-B Antioxidants MERCK PATENT GMBH 2012-09-05 CN disclosed
US-8106233-B2 Applying di-2-ethylhexyl 4-hydroxy-3,5-dimethoxy-benzylmalonate; protective action against UV rays, oxidative stress on body cells, counters skin ageing MERCK PATENT GMBH (DE) 2012-01-31 US disclosed
US-20080171004-A1 Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives MERCK PATENT GMBH (DE) 2008-07-17 US disclosed
US-20080152603-A1 Antioxidants SUSONITY Commercial GmbH (DE) 2008-06-26 US disclosed
CN-101203278-A Ultraviolet protection MERCK PATENT GMBH (DE) 2008-06-18 CN disclosed
CN-101163659-A Antioxidants MERCK PATENT GMBH (DE) 2008-04-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080152603-A1 Antioxidants GPX4, GPX1, CAT CA12 3215/4885CA1 2392/4885CA2 1558/4885
US-20080171004-A1 Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives HPD, HAAO, UGT1A6 CA12 2109/4885CA1 2587/4885CA2 2547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.